Anavex Life Sciences Reports Long-Term Blarcamesine Benefits For Early Alzheimer's Patients
5/4 18:12
(RTTNews) - Anavex Life Sciences Corp. (AVXL) announced that more than three years of continuous treatment with blarcamesine (ANAVEX 2-73) significantly improved clinical decline, demonstrating sustained and meaningful benefits for early Alzheimer's disease patients, according to...